Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
Not yet recruiting · NCT07694414 · Registry updated 2026-07-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Not yet recruiting | Phase 1 | 2026-07-22 | NCT07694414 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Inge Marie Svane | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital | Herlev | Denmark | 2 |